A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

A nurse has warned about a common Mounjaro ‘mistake’ that can increase people’s risk of deadly organ damage.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. ... like high blood pressure or high cholesterol. Professor Louis Aronne from Weill Cornell Medicine.

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity. ... (such as high blood pressure, type 2 diabetes or high cholesterol). ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in ... (such as high blood pressure, type 2 diabetes or high ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

The researchers found that participants who lost at least 35% of their body weight from baseline to week 72 had mean changes of up to –14.2 and –9.2 mm Hg for systolic and diastolic blood ...